Dr. Reddy's Reports 36% Q2 PAT Drop, Supports Trade Margin Cap
In Q2 FY2027, Dr. Reddy's Laboratories saw a 36% decline in profit after tax along with reduced revenue. The company endorses new trade margin caps designed to enhance access to essential medicines. Management remains focused on strengthening core business performance while actively seeking new growth opportunities.
ET Markets·




